How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,193 results for

Amenorrhea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Functional Hypothalamic Amenorrhea

Functional Hypothalamic Amenorrhea '); '); Hypothalamic Amenorrhea Guideline Resources | Endocrine Society Hormone Science to Health / › › › Guidelines and Clinical Practice Section + Hypothalamic Amenorrhea Guideline Resources Full Guideline: JCEM | March 2017 Catherine M. Gordon (chair), Kathryn E. Ackerman, Sarah L. Berga, Jay R. Kaplan, George Mastorakos, Madhusmita Misra, M. Hassan Murad, Nanette F. Santoro, and Michelle P. Warren The 2017 guideline addresses: Diagnosing functional (...) hypothalamic amenorrhea (FHA) Evaluating causal and concomitant conditions, including mental disorders Deciding which laboratory and imaging tests should be performed Treating FHA and concomitant conditions with lifestyle changes and hormone therapy, and providing fertility treatments for women with FHA Resources | ENDO 2017 | ENDO 2017 | Guideline Central | Endocrine News | Hormone Health Network | Endocrine Society Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline Essential Points

2017 The Endocrine Society

3. Bone Parameters in Anorexia Nervosa and Athletic Amenorrhea: Comparison of Two Hypothalamic Amenorrhea States. (PubMed)

Bone Parameters in Anorexia Nervosa and Athletic Amenorrhea: Comparison of Two Hypothalamic Amenorrhea States. We have reported low bone mineral density (BMD), impaired bone structure, and increased fracture risk in participants with anorexia nervosa (AN) and normal-weight oligoamenorrheic athletes (OAs). However, data directly comparing compartment-specific bone parameters in participants with AN, OAs, and controls are lacking.A total of 468 female participants 14 to 21.9 years old were

Full Text available with Trip Pro

2018 Journal of Clinical Endocrinology and Metabolism

4. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis

Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis Amenorrhea is a polarizing noncontraceptive effect of the levonorgestrel intrauterine system. Composite amenorrhea prevalence estimates that summarize all clinical data for the first-year after insertion currently are not available. The purpose of this study was to investigate the validity of existing prevalence estimates by the systematic calculation of amenorrhea measures for a general population (...) of levonorgestrel intrauterine system users and to provide 90-day interval point estimates for the first year of use.We identified clinical trials, randomized controlled trials, and randomized comparative trials that were published in English between January 1970 and September 2017 through electronic searches of 12 biomedical and scientific literature databases that included MEDLINE and ClinicalTrials.gov.We considered studies that clearly defined amenorrhea per World Health Organization standards (the complete

Full Text available with Trip Pro

2019 EvidenceUpdates

5. Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes (PubMed)

Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated.Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared (...) with clinicopathologic features and survival. SPSS version 17 was used.Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p= 0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs

Full Text available with Trip Pro

2018 European journal of breast health

6. Treatments to Prevent Bone Loss in Functional Hypothalamic Amenorrhea: A Systematic Review and Meta-Analysis. (PubMed)

Treatments to Prevent Bone Loss in Functional Hypothalamic Amenorrhea: A Systematic Review and Meta-Analysis. We conducted a systematic review and meta-analysis of studies that evaluated the effect of hormonal therapy [estrogen therapy including oral contraceptive pills (OCP)] and bisphosphonates in preventing bone loss in patients with functional hypothalamic amenorrhea (FHA).We searched several electronic databases for controlled and noncontrolled studies that enrolled females of any age (...) presenting with FHA (including athletic, weight loss, and stress-associated amenorrhea/oligomenorrhea) through 9 January 2017. The outcomes of interest were fractures and bone mineral density (BMD). Random effects meta-analysis was used to pool outcomes across studies expressed as weighted mean difference and 95% confidence interval (CI).Nine studies reporting on 280 patients that received different hormonal therapies were included. We did not identify studies that evaluated bisphosphonates. Meta

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

7. Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents (PubMed)

Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents The treatment of persistent uterine bleeding in those patients who identify as transmasculine or nonbinary is often straightforward, but can be difficult in a subset of patients. This article reviews the physiology of the normal menstrual cycle and the hormonal influences on the endometrium, and then explores options for the treatment of persistent bleeding for people both already on testosterone and for those

Full Text available with Trip Pro

2017 Transgender health

8. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea (PubMed)

Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea Hyperprolactinemia-induced hypogonadotropic amenorrhea (hPRL-HA) is a major cause of hypothalamic gonadotrophin-releasing hormone (GnRH) deficiency in women. In hyperprolactinemic mice, we previously demonstrated that hypothalamic kisspeptin (Kp) expression was diminished and that Kp administration restored hypothalamic GnRH release, gonadotropin secretion, and ovarian cyclicity

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

9. Laboratory Endocrine Testing Guidelines: Amenorrhea (without Hirsutism) and Menopause

Laboratory Endocrine Testing Guidelines: Amenorrhea (without Hirsutism) and Menopause LABORATORY ENDOCRINE TESTING: AMENHORRHEA (WITHOUT HIRSUTISM) AND MENOPAUSE Clinical Practice Guideline | January 2008 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Clinicians in Alberta optimize laboratory (...) tests for investigation of amenorrhea (without hirsutism) and suspected menopause TARGET POPULATION Women with primary amenorrhea Girls with the lack of breast development by age 14 years, or by the lack of menses by age 16 in the presence of normal secondary sexual development, or by the lack of menses by three years after the larche Women with secondary amenorrhea (more than six months without menses after prior establishment of menses) EXCLUSIONS Pregnant women RECOMMENDATIONS PRIMARY AMENORRHEA

2014 Toward Optimized Practice

10. Increased Anti Mullerian Hormone levels and ovarian size in a subgroup of women with Functional Hypothalamic Amenorrhea : Further identification of the link between Polycystic Ovary Syndrome and Functional Hypothalamic Amenorrhea. (PubMed)

Increased Anti Mullerian Hormone levels and ovarian size in a subgroup of women with Functional Hypothalamic Amenorrhea : Further identification of the link between Polycystic Ovary Syndrome and Functional Hypothalamic Amenorrhea. Functional hypothalamic amenorrhea is a disorder characterized by cessation of menstrual cycles in the absence of organic disease. In most patients, it occurs in adult life after a stressful event and may be related to a condition of mild chronic energy deprivation (...) : functional hypothalamic amenorrhea and polycystic ovary syndrome. The importance of the possible coexistence of these disorders in some women is important for follow-up of these women and in their treatment if they desire to become pregnant.To determine whether a subgroup of well-characterized women with functional hypothalamic amenorrhea may have the coexistence of polycystic ovary syndrome.Retrospective analysis of women with functional hypothalamic amenorrhea. Forty consecutive patients and 28 normal

2016 American Journal of Obstetrics and Gynecology

11. Treatment of postpill amenorrhea with abdominal obesity by traditional Korean medicine treatment focused on pharmacopuncture and moxibustion: A case report. (PubMed)

Treatment of postpill amenorrhea with abdominal obesity by traditional Korean medicine treatment focused on pharmacopuncture and moxibustion: A case report. Hormone imbalance and menstrual irregularities are normal for postpill women. Pharmacopuncture and moxibustion can stimulate acupoints with herbal extract and heat, respectively, to regulate the function of qi and blood, expel pathogens, and support health.A 39-year-old female patient presented with amenorrhea, >6 months after she had (...) stopped taking the oral contraceptive pill, which she had taken for more than 10 years, and possible associated infertility. Additionally, she reported sudden weight gain of approximately 12 kg in 1 year.In this study, we examined the amenorrhea lasted more than 6 months for postpill patient.She refused a strong acupuncture stimulus; she underwent lower abdomen pharmacopuncture with wild ginseng complex (WGC) and moxibustion at CV4, 5 times during 1 month. As a secondary treatment, 1 g Geoseub-hwan

2019 Medicine

12. FXPOI: Pattern of AGG Interruptions Does not Show an Association With Age at Amenorrhea Among Women With a Premutation (PubMed)

FXPOI: Pattern of AGG Interruptions Does not Show an Association With Age at Amenorrhea Among Women With a Premutation Fragile X-associated primary ovarian insufficiency (FXPOI) occurs in about 20% of women who carry a premutation allele (55-200 CGG repeats). These women develop hypergonadotropic hypogonadism and have secondary amenorrhea before age 40. A non-linear association with repeat size and risk for FXPOI has been seen in multiple studies women with a premutation: those with a mid-range (...) of repeats are at highest risk (∼70-100 CGG repeats). Importantly, not all carriers with 70-100 repeats experience FXPOI. We investigated whether AGG interruptions, adjusted for repeat size, impacted age at secondary amenorrhea. We have reproductive history information and AGG interruption data on 262 premutation women: 164 had an established age at amenorrhea (AAA) (for some, age at onset of FXPOI) or menopause, 16 had a surgery involving the reproductive system such as a hysterectomy, and 82 women were

Full Text available with Trip Pro

2018 Frontiers in genetics

13. Müllerian Agenesis Masquerading as Secondary Amenorrhea (PubMed)

Müllerian Agenesis Masquerading as Secondary Amenorrhea The most common cause of primary amenorrhea is congenital malformation of the Müllerian ducts, including Müllerian agenesis, also known as Mayer-Rokitansky-Küster-Hauser syndrome (MRKH). Most general gynecologists and primary care physicians who see female adolescents will encounter MRKH in their careers. We present the case of an adolescent with MRKH who reported secondary, instead of primary amenorrhea. We discuss the subtleties

Full Text available with Trip Pro

2018 Case reports in pediatrics

14. Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea (PubMed)

Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea In patients with chemotherapy-induced amenorrhea (CIA), the menopausal status is ambiguous and difficult to evaluate. This study aimed to establish a discriminative model to predict and classify the menopausal status of breast cancer patients with CIA.This is a single center hospital-based study from 2013 to 2016. The menopausal age distribution and accumulated incidence rate of CIA are described

Full Text available with Trip Pro

2018 Chinese Journal of Cancer Research

15. Sellar chondrosarcoma presenting with amenorrhea: A case report. (PubMed)

Sellar chondrosarcoma presenting with amenorrhea: A case report. Intracranial chondrosarcomas are rare entities and most of which arise off the midline. Chondrosarcomas that occur in the sellar region are extremely rare, and to the best of our knowledge, there is no reporting about sellar chondrosarcoma with amenorrhea as the onset symptom.A 45-year-old woman presented with a 7-month history of amenorrhea and a 3-month history of progressive visual loss in the left eye.The patient was diagnosed

Full Text available with Trip Pro

2018 Medicine

16. Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. (PubMed)

Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. To systematically review and appraise the existing evidence in relation to the efficacy and safety of pulsatile gonadotropin-releasing hormone (pGnRH) for the treatment of women with hypothalamic amenorrhea (HA).Systematic review and meta-analysis.Not applicable.A total of 35 studies (three

2018 Fertility and Sterility

17. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. (PubMed)

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. In premenopausal patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, the gonadotoxicity of trastuzumab and lapatinib remains largely uncertain, and the prognostic effect of treatment-related amenorrhea (TRA) is unknown.In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (BIG 2-06) phase III trial, HER2

Full Text available with Trip Pro

2018 Journal of the National Cancer Institute

18. The effect of hormone therapy on bone mineral density and cardiovascular factors among Iranian female athletes with amenorrhea/oligomenorrhea: A randomized clinical trial (PubMed)

The effect of hormone therapy on bone mineral density and cardiovascular factors among Iranian female athletes with amenorrhea/oligomenorrhea: A randomized clinical trial Background: Functional hypothalamic menstrual disorder (FHMD) has a destructive effect on the athlete's bone mineral density and cardiovascular system. Utilizing hormone replacement therapy to treat FHMD in athletes is controversial. This study was conducted to examine the effect of hormone therapy on bone density

Full Text available with Trip Pro

2018 Medical journal of the Islamic Republic of Iran

19. Description of Practices Implemented in the Birth of Living Children Before 24 Weeks of Amenorrhea

Description of Practices Implemented in the Birth of Living Children Before 24 Weeks of Amenorrhea Description of Practices Implemented in the Birth of Living Children Before 24 Weeks of Amenorrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Description of Practices Implemented in the Birth of Living Children Before 24 Weeks of Amenorrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03403894 Recruitment Status

2018 Clinical Trials

20. Efficacy of a Herbal Formulation Based on Foeniculum Vulgare in Oligo/Amenorrhea: A Randomized Clinical Trial. (PubMed)

Efficacy of a Herbal Formulation Based on Foeniculum Vulgare in Oligo/Amenorrhea: A Randomized Clinical Trial. The aim of this study was to evaluate the efficacy of the herbal tea based on Foeniculum vulgare, on inducing regular bleeding in women with oligomenorrhea and secondary amenorrhea(oligo/amenorrhea).Forty women aged 18- 40 with oligo/amenorrhea were enrolled in this randomized controlled clinical trial and were allocated to two groups equally. The women in the first group were treated

2018 Current drug discovery technologies

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>